These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

197 related articles for article (PubMed ID: 35423696)

  • 1. Binding selectivity of inhibitors toward the first over the second bromodomain of BRD4: theoretical insights from free energy calculations and multiple short molecular dynamics simulations.
    Wang Y; Wu S; Wang L; Yang Z; Zhao J; Zhang L
    RSC Adv; 2020 Dec; 11(2):745-759. PubMed ID: 35423696
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Selectivity Mechanism of Pyrrolopyridone Analogues Targeting Bromodomain 2 of Bromodomain-Containing Protein 4 from Molecular Dynamics Simulations.
    Shi M; Zheng X; Zhou Y; Yin Y; Lu Z; Zou Z; Hu Y; Liang Y; Chen T; Yang Y; Jing M; Lei D; Yang P; Li X
    ACS Omega; 2023 Sep; 8(37):33658-33674. PubMed ID: 37744850
    [TBL] [Abstract][Full Text] [Related]  

  • 3. A theoretical insight into selectivity of inhibitors toward two domains of bromodomain-containing protein 4 using molecular dynamics simulations.
    Su J; Liu X; Zhang S; Yan F; Zhang Q; Chen J
    Chem Biol Drug Des; 2018 Mar; 91(3):828-840. PubMed ID: 29139214
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Revealing binding selectivity of inhibitors toward bromodomain-containing proteins 2 and 4 using multiple short molecular dynamics simulations and free energy analyses.
    Wang LF; Wang Y; Yang ZY; Zhao J; Sun HB; Wu SL
    SAR QSAR Environ Res; 2020 May; 31(5):373-398. PubMed ID: 32496901
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Computational study on the selective inhibition mechanism of MS402 to the first and second bromodomains of BRD4.
    Wang Q; Li Y; Xu J; Wang Y; Shi D; Liu L; Leung EL; Yao X
    Proteins; 2019 Jan; 87(1):3-11. PubMed ID: 30260047
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Binding pocket-based design, synthesis and biological evaluation of novel selective BRD4-BD1 inhibitors.
    Ma J; Chen H; Yang J; Yu Z; Huang P; Yang H; Zheng B; Liu R; Li Q; Hu G; Chen Z
    Bioorg Med Chem; 2019 May; 27(9):1871-1881. PubMed ID: 30926312
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Discovery and characterization of bromodomain 2-specific inhibitors of BRDT.
    Yu Z; Ku AF; Anglin JL; Sharma R; Ucisik MN; Faver JC; Li F; Nyshadham P; Simmons N; Sharma KL; Nagarajan S; Riehle K; Kaur G; Sankaran B; Storl-Desmond M; Palmer SS; Young DW; Kim C; Matzuk MM
    Proc Natl Acad Sci U S A; 2021 Mar; 118(9):. PubMed ID: 33637650
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Selective inhibition mechanism of RVX-208 to the second bromodomain of bromo and extraterminal proteins: insight from microsecond molecular dynamics simulations.
    Wang Q; Li Y; Xu J; Wang Y; Leung EL; Liu L; Yao X
    Sci Rep; 2017 Aug; 7(1):8857. PubMed ID: 28821780
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Deciphering the mechanisms of selective inhibition for the tandem BD1/BD2 in the BET-bromodomain family.
    Cheng C; Diao H; Zhang F; Wang Y; Wang K; Wu R
    Phys Chem Chem Phys; 2017 Sep; 19(35):23934-23941. PubMed ID: 28849824
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Pyronaridine as a Bromodomain-Containing Protein 4-
    Ibrahim MAA; Abdelhamid MMH; Abdeljawaad KAA; Abdelrahman AHM; Mekhemer GAH; Sidhom PA; Sayed SRM; Paré PW; Hegazy MF; Shoeib T
    Molecules; 2023 Jul; 28(15):. PubMed ID: 37570684
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Discovery of
    Sheppard GS; Wang L; Fidanze SD; Hasvold LA; Liu D; Pratt JK; Park CH; Longenecker K; Qiu W; Torrent M; Kovar PJ; Bui M; Faivre E; Huang X; Lin X; Wilcox D; Zhang L; Shen Y; Albert DH; Magoc TJ; Rajaraman G; Kati WM; McDaniel KF
    J Med Chem; 2020 May; 63(10):5585-5623. PubMed ID: 32324999
    [TBL] [Abstract][Full Text] [Related]  

  • 12. The binding mechanism of NHWD-870 to bromodomain-containing protein 4 based on molecular dynamics simulations and free energy calculation.
    Shi M; He J; Weng T; Shi N; Qi W; Guo Y; Chen T; Chen L; Xu D
    Phys Chem Chem Phys; 2022 Feb; 24(8):5125-5137. PubMed ID: 35156677
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Discovery of novel BRD4-BD2 inhibitors via in silico approaches: QSAR techniques, molecular docking, and molecular dynamics simulations.
    Tong JB; Xiao XC; Luo D; Xu HY; Xing YC; Gao P; Liu Y
    Mol Divers; 2024 Apr; 28(2):671-692. PubMed ID: 36773087
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Discovery of the natural product 3',4',7,8-tetrahydroxyflavone as a novel and potent selective BRD4 bromodomain 2 inhibitor.
    Li J; Zou W; Yu K; Liu B; Liang W; Wang L; Lu Y; Jiang Z; Wang A; Zhu J
    J Enzyme Inhib Med Chem; 2021 Dec; 36(1):903-913. PubMed ID: 33820450
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Identification of potent BRD4-BD1 inhibitors using classical and steered molecular dynamics based free energy analysis.
    Gupta A; Purohit R
    J Cell Biochem; 2024 Mar; 125(3):e30532. PubMed ID: 38317535
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Discovery of potent BET bromodomain 1 stereoselective inhibitors using DNA-encoded chemical library selections.
    Modukuri RK; Yu Z; Tan Z; Ta HM; Ucisik MN; Jin Z; Anglin JL; Sharma KL; Nyshadham P; Li F; Riehle K; Faver JC; Duong K; Nagarajan S; Simmons N; Palmer SS; Teng M; Young DW; Yi JS; Kim C; Matzuk MM
    Proc Natl Acad Sci U S A; 2022 May; 119(22):e2122506119. PubMed ID: 35622893
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Structure-Guided Design and Synthesis of Pyridinone-Based Selective Bromodomain and Extra-Terminal Domain (BET)-First Bromodomain (BD1) Inhibitors.
    Li Y; Shen Z; Ratia K; Zhao J; Huang F; Dubrovyskyii O; Indukuri D; Fu J; Lozano Ramos O; Thatcher GRJ; Xiong R
    J Med Chem; 2024 Feb; 67(4):2712-2731. PubMed ID: 38295759
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Discovery of a Bromodomain and Extra Terminal Domain (BET) Inhibitor with the Selectivity for the Second Bromodomain (BD2) and the Capacity for the Treatment of Inflammatory Diseases.
    Wang Z; Yin L; Xiong Z; Huang F; Yang N; Jiang F; Li H; Cui Y; Ren J; Cheng Z; Jia K; Lu T; Zhu J; Hu Q; Chen Y
    J Med Chem; 2023 Aug; 66(15):10824-10848. PubMed ID: 37478496
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Classical molecular dynamics and metadynamics simulations decipher the mechanism of CBP30 selectively inhibiting CBP/p300 bromodomains.
    Wang Q; An X; Xu J; Wang Y; Liu L; Leung EL; Yao X
    Org Biomol Chem; 2018 Sep; 16(35):6521-6530. PubMed ID: 30160288
    [TBL] [Abstract][Full Text] [Related]  

  • 20. BETting on next-generation bromodomain inhibitors.
    Collins MK; Chau CH; Price DK; Figg WD
    Am J Clin Exp Urol; 2020; 8(4):129-132. PubMed ID: 32929408
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.